A similar trial (NCT06517212) will focus primarily on breast cancer–related outcomes, aiming to determine whether tirzepatide-induced weight loss prevents the development of metastatic disease and improves disease-free survival in patients with HR-positive, HER2-negative high-risk breast cancer. Here, ERBB2 is linked to breast carcinoma.